Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

To increase the valency, stability and therapeutic potential of bispecific antibodies, we designed a novel recombinant molecule that is bispecific and tetravalent. It was constructed by linking four antibody variable domains (VHand VL) with specificities for human CD3 (T cell antigen) or CD19 (B cell marker) into a single chain construct. After expression in Escherichia coli, intramolecularly folded bivalent bispecific antibodies with a mass of 57 kDa (single chain diabodies) and tetravalent bispecific dimers with a molecular mass of 114 kDa (tandem diabodies) could be isolated from the soluble periplasmic extracts. The relative amount of tandem diabodies proved to be dependent on the length of the linker in the middle of the chain and bacterial growth conditions. Compared to a previously constructed heterodimeric CD3xCD19 diabody, the tandem diabodies exhibited a higher apparent affinity and slower dissociation from both CD3(+)and CD19(+)cells. They were also more effective than diabodies in inducing T cell proliferation in the presence of tumor cells and in inducing the lysis of CD19(+)cells in the presence of activated human PBL. Incubated in human serum at 37 degrees C, the tandem diabody retained 90 % of its antigen binding activity after 24 hours and 40 % after one week. In vivo experiments indicated a higher stability and longer blood retention of tandem diabodies compared to single chain Fv fragments and diabodies, properties that are particularly important for potential clinical applications.

[1]  D. Eisenberg,et al.  Domain swapping: entangling alliances between proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Little,et al.  Bispecific CD3 × CD19 diabody for T cell‐mediated lysis of malignant human B cells , 1998 .

[3]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Winter,et al.  Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. , 1997, Protein engineering.

[5]  V. Diehl,et al.  Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. , 1993, Blood.

[6]  M. Little,et al.  Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. , 1996, Journal of immunological methods.

[7]  L. Nieba,et al.  Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. , 1997, Protein engineering.

[8]  E. Voss,et al.  Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20 , 1996, The Journal of Biological Chemistry.

[9]  M. Glennie,et al.  Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. , 1987, Journal of immunology.

[10]  K. Kleppe,et al.  Cloning and sequencing of the gene for the DNA-binding 17 K protein of Escherichia coli , 1988 .

[11]  R. Williams,et al.  Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. , 1996, Protein engineering.

[12]  M. Little,et al.  Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding , 1999, FEBS letters.

[13]  A. Plückthun,et al.  The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies , 1998, FEBS letters.

[14]  A. Plückthun,et al.  Selection for a periplasmic factor improving phage display and functional periplasmic expression , 1998, Nature Biotechnology.

[15]  M. Little,et al.  High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. , 1997, Journal of immunological methods.

[16]  M. Little,et al.  Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. , 1997, Protein engineering.

[17]  P. Matzinger.  The JAM test. A simple assay for DNA fragmentation and cell death. , 1991, Journal of immunological methods.

[18]  M. Little,et al.  Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. , 1996, Protein engineering.

[19]  E. Reinherz,et al.  Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.

[20]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[21]  R. Williams,et al.  Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.

[22]  B. Dörken,et al.  CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. , 1987, Journal of immunology.

[23]  Michaela A. E. Arndt,et al.  A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. , 1999, Blood.

[24]  L. Presta,et al.  Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.

[25]  T. Logtenberg,et al.  Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library (*) , 1996, The Journal of Biological Chemistry.

[26]  D. Kranz,et al.  Binding affinity and inhibitory properties of a single-chain anti-T cell receptor antibody. , 1993, The Journal of biological chemistry.

[27]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Schlom,et al.  The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli. , 1994, Protein engineering.

[29]  G. Adams,et al.  Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.

[30]  E. Wagner,et al.  Mechanism of post‐segregational killing: Sok antisense RNA interacts with Hok mRNA via its 5′‐end single‐stranded leader and competes with the 3′‐end of Hok mRNA for binding to the mok translational initiation region. , 1994, The EMBO journal.

[31]  S. N. Timasheff,et al.  Mechanism of the stabilization of ribonuclease a by sorbitol: Preferential hydration is greater for the denatured than for the native protein , 1997, Protein science : a publication of the Protein Society.

[32]  L J Harris,et al.  Crystallographic structure of an intact IgG1 monoclonal antibody. , 1998, Journal of molecular biology.

[33]  A. Plückthun,et al.  High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions , 1996, Applied Microbiology and Biotechnology.

[34]  A. Plückthun,et al.  Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. , 1998, Biochemistry.

[35]  K. Tsumoto,et al.  Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. , 1998, Journal of immunological methods.

[36]  M. Polymenis,et al.  Domain interactions and antigen binding of recombinant anti-Z-DNA antibody variable domains. The role of heavy and light chains measured by surface plasmon resonance. , 1995, Journal of immunology.

[37]  A. Lobuglio,et al.  Human immune response to monoclonal antibodies. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[38]  G. A. Bowden,et al.  Folding and aggregation of beta-lactamase in the periplasmic space of Escherichia coli. , 1990, The Journal of biological chemistry.

[39]  M. Ptashne,et al.  Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. , 1980, Journal of molecular biology.

[40]  A. Plückthun,et al.  A dimeric bispecific miniantibody combines two specificities with avidity , 1998, FEBS letters.

[41]  T. Arakawa,et al.  The stabilization of proteins by osmolytes. , 1985, Biophysical journal.

[42]  R. Begent,et al.  Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. , 1995, Journal of immunological methods.

[43]  S. Dübel,et al.  Thiophilic adsorption chromatography of recombinant single-chain antibody fragments. , 1994, Analytical biochemistry.

[44]  J. Ledbetter,et al.  Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Schmitz,et al.  Generation of Rabbit Monoclonal Antibody Fragments from a Combinatorial Phage Display Library and Their Production in the Yeast Pichia pastoris , 1995, Bio/Technology.

[46]  Tirso Pons,et al.  Homology modeling, model and software evaluation: three related resources , 1998, Bioinform..

[47]  M. Little,et al.  Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. , 1994, Molecular immunology.

[48]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[49]  P F Davison,et al.  Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. , 1985, Science.

[50]  A. Collins,et al.  Humanization of the murine anti-human CD3 monoclonal antibody OKT3. , 1994, Human antibodies and hybridomas.

[51]  Adams Gp.  Improving the tumor specificity and retention of antibody-based molecules. , 1998 .

[52]  A. Plückthun,et al.  Tandem immobilized metal-ion affinity chromatography/immunoaffinity purification of His-tagged proteins--evaluation of two anti-His-tag monoclonal antibodies. , 1998, Analytical biochemistry.

[53]  D. Segal,et al.  Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. , 1995, Journal of immunology.

[54]  Ronald T. Raines,et al.  Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments , 1998, Nature Biotechnology.

[55]  J. Lee,et al.  The stabilization of proteins by sucrose. , 1981, The Journal of biological chemistry.

[56]  J R Blackwell,et al.  A novel strategy for production of a highly expressed recombinant protein in an active form , 1991, FEBS letters.

[57]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[58]  B. Snedecor,et al.  High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli , 1996, Bio/Technology.

[59]  D. Givol,et al.  The minimal antigen-binding fragment of antibodies--Fv fragment. , 1991, Molecular immunology.

[60]  P. Carter,et al.  Toward the production of bispecific antibody fragments for clinical applications. , 1995, Journal of hematotherapy.

[61]  D. Kranz,et al.  Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. , 1994, Journal of immunology.

[62]  K. Arndt,et al.  A dimeric bispeci¢c miniantibody combines two speci¢cities with avidity , 1998 .

[63]  R. Glockshuber,et al.  A comparison of strategies to stabilize immunoglobulin Fv-fragments. , 1990, Biochemistry.

[64]  S. Morrison,et al.  Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.

[65]  D Eisenberg,et al.  Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. , 1997, Advances in protein chemistry.